People | June 17, 2022
Valo Therapeutics appoints Hemanshu Shah as Chief Business Officer
We see significant potential in working with oncolytic virus companies and Neo antigen-companies
We see significant potential in working with oncolytic virus companies and Neo antigen-companies
The innovative software module is designed to meet growing scientific demand from researchers and drug developers
Gilman will be responsible for all business development and portfolio strategy efforts globally.
Acceptance based on results from the phase 3 KEYNOTE-091 trial
Group 4 Medulloblastoma is a rare disease that mostly affects pediatric patients, in which aberrant SRC signaling was identified as a hallmark of the disease
India’s first oncology laboratory for comprehensive Cancer Diagnostic services
Tislelizumab is now approved in nine indications in China
Healthcare is timely and personal – and its delivery should be too
If approved, Tafinlar + Mekinist may offer a potential new standard-of-care for pediatric patients with this brain cancer
Scemblix (asciminib) continues to show superior efficacy with more-than-two-fold improvement in major molecular response rate vs. Bosulif (bosutinib) at 96 weeks
Subscribe To Our Newsletter & Stay Updated
